First patient receives anti-CD24 macrophage checkpoint inhibitor
Pheast Therapeutics has treated the first patient in its Phase I clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumours. The study will enrol up to 80 patients with advanced relapsed and/or refractory solid tumours. The study’s primary objectives… Read More